inclusion criteria: 1. positive rt-pcr assay for sars-cov-2; 2. covid-19 disease requiring hospitalization 3. dyspnea at rest or during minimal activity (sitting, talking, coughing, swallowing), or * respiratory rate \> 22/min, or * pao2 \< 65mmhg or o2sat \< 90%, or * infiltrate on chest radiography (cxr) (worsening cxr if baseline abnormal) 4. age ≥18 years; 5. ability to provide consent or to provide consent via a substitute decision maker patients who are pregnant may also be eligible if consent is provided. patients who have received one of the sars-cov2 vaccines and/or bamlanivimab are eligible to participate in the study

inclusion criteria: 1. positive rt-pcr assay for sars-cov-2; 2. covid-19 disease requiring hospitalization 3. dyspnea at rest or during minimal activity (sitting, talking, coughing, swallowing), or * respiratory rate \> 22/min, or * pao2 \< 65mmhg or o2sat \< 90%, or * infiltrate on chest radiography (cxr) (worsening cxr if baseline abnormal) 4. age ≥18 years; 5. ability to provide consent or to provide consent via a substitute decision maker patients who are pregnant may also be eligible if consent is provided. patients who have received one of the sars-cov2 vaccines and/or bamlanivimab are eligible to participate in the study

inclusion criteria: positive rt-pcr assay for sars-cov-2; covid-19 disease requiring hospitalization dyspnea at rest or during minimal activity (sitting, talking, coughing, swallowing), or respiratory rate > 22/min, or pao2 < 65mmhg or o2sat < 90%, or infiltrate on chest radiography (cxr) (worsening cxr if baseline abnormal) age ≥18 years; ability to provide consent or to provide consent via a substitute decision maker patients who are pregnant may also be eligible if consent is provided. patients who have received one of the sars-cov2 vaccines and/or bamlanivimab are eligible to participate in the study

inclusion criteria: positive rt-pcr assay for sars-cov-2; covid-19 disease requiring hospitalization dyspnea at rest or during minimal activity (sitting, talking, coughing, swallowing), or respiratory rate > 22/min, or pao2 < 65mmhg or o2sat < 90%, or infiltrate on chest radiography (cxr) (worsening cxr if baseline abnormal) age ≥18 years; ability to provide consent or to provide consent via a substitute decision maker patients who are pregnant may also be eligible if consent is provided. patients who have received one of the sars-cov2 vaccines and/or bamlanivimab are eligible to participate in the study

inclusion criteria: 1. positive rt-pcr assay for sars-cov-2; 2. covid-19 disease requiring hospitalization 3. dyspnea at rest or during minimal activity (sitting, talking, coughing, swallowing), or - respiratory rate > 22/min, or - pao2 < 65mmhg or o2sat < 90%, or - infiltrate on chest radiography (cxr) (worsening cxr if baseline abnormal) 4. age ≥18 years; 5. ability to provide consent or to provide consent via a substitute decision maker patients who are pregnant may also be eligible if consent is provided. patients who have received one of the sars-cov2 vaccines and/or bamlanivimab are eligible to participate in the study

inclusion criteria: 1. positive rt-pcr assay for sars-cov-2; 2. covid-19 disease requiring hospitalization 3. dyspnea at rest or during minimal activity (sitting, talking, coughing, swallowing), or - respiratory rate > 22/min, or - pao2 < 65mmhg or o2sat < 90%, or - infiltrate on chest radiography (cxr) (worsening cxr if baseline abnormal) 4. age ≥18 years; 5. ability to provide consent or to provide consent via a substitute decision maker patients who are pregnant may also be eligible if consent is provided. patients who have received one of the sars-cov2 vaccines and/or bamlanivimab are eligible to participate in the study

inclusion criteria: - positive rt-pcr assay for sars-cov-2 - disease requiring hospitalization: dyspnea at rest or during minimal activity (sitting talking, coughing, swallowing), or respiratory rate > 22/min, or pao2 < 65mmhg or o2sat < 90%, or infiltrate on chest radiography (cxr) (worsening cxr if baseline abnormal) - age ≥18 years - history of comorbid disease, where omalizumab efficacy and safety is well established: chronic spontaneous urticaria (csu) or atopy (e.g. atopic dermatitis, food allergies, hay fever) or asthma or copd with evidence of type 2 inflammation (self-reported history of asthma, atopic diathesis or with elevated eosinophil percentage as surrogate for th2 disease) or elevated baseline serum ige levels (if available).

inclusion criteria: - positive rt-pcr assay for sars-cov-2 - disease requiring hospitalization: dyspnea at rest or during minimal activity (sitting talking, coughing, swallowing), or respiratory rate > 22/min, or pao2 < 65mmhg or o2sat < 90%, or infiltrate on chest radiography (cxr) (worsening cxr if baseline abnormal) - age ≥18 years - history of comorbid disease, where omalizumab efficacy and safety is well established: chronic spontaneous urticaria (csu) or atopy (e.g. atopic dermatitis, food allergies, hay fever) or asthma or copd with evidence of type 2 inflammation (self-reported history of asthma, atopic diathesis or with elevated eosinophil percentage as surrogate for th2 disease) or elevated baseline serum ige levels (if available).